JP2021523170A5 - - Google Patents
Info
- Publication number
- JP2021523170A5 JP2021523170A5 JP2020563542A JP2020563542A JP2021523170A5 JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5 JP 2020563542 A JP2020563542 A JP 2020563542A JP 2020563542 A JP2020563542 A JP 2020563542A JP 2021523170 A5 JP2021523170 A5 JP 2021523170A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- neutralizing agent
- combination according
- nkg2a
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059910A JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671521P | 2018-05-15 | 2018-05-15 | |
| US62/671,521 | 2018-05-15 | ||
| PCT/EP2019/062305 WO2019219658A1 (en) | 2018-05-15 | 2019-05-14 | Treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059910A Division JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523170A JP2021523170A (ja) | 2021-09-02 |
| JP2021523170A5 true JP2021523170A5 (cg-RX-API-DMAC7.html) | 2022-05-26 |
| JP7531404B2 JP7531404B2 (ja) | 2024-08-09 |
Family
ID=66752041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563542A Active JP7531404B2 (ja) | 2018-05-15 | 2019-05-14 | 癌の処置 |
| JP2024059910A Pending JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059910A Pending JP2024102055A (ja) | 2018-05-15 | 2024-04-03 | 癌の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12209126B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3793607A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7531404B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102885515B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112203691A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019270277B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3099820A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202092696A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278618B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA52627A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202011117VA (cg-RX-API-DMAC7.html) |
| TW (1) | TW202011989A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019219658A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
| WO2021219048A1 (zh) * | 2020-04-30 | 2021-11-04 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| EP4150058A4 (en) * | 2020-05-13 | 2024-06-19 | Nanjing Legend Biotech Co., Ltd. | COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF |
| CN117730094A (zh) * | 2021-07-16 | 2024-03-19 | 克莱格医学有限公司 | 用于肿瘤免疫学的组合物和方法 |
| IL311736A (en) * | 2021-10-04 | 2024-05-01 | Servier Lab | Cancer therapy targeting nkg2a |
| CA3241115A1 (en) * | 2021-12-14 | 2023-06-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to cd94/nkg2a heterodimer polypeptides |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| CA2487932A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| RU2481356C2 (ru) | 2004-12-28 | 2013-05-10 | Иннейт Фарма | Моноклональные антитела против nkg2a |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| DK2038306T3 (en) | 2006-06-30 | 2015-03-09 | Novo Nordisk As | ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| MX2010007935A (es) | 2008-01-24 | 2010-08-23 | Novo Nordisk As | Anticuerpo monoclonal humanizado anti-nkg2a humano. |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| MX342131B (es) | 2011-06-17 | 2016-09-14 | Novo Nordisk As | Eliminacion selectiva de celulas erosivas. |
| RU2017105425A (ru) * | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| KR20250007689A (ko) * | 2014-09-16 | 2025-01-14 | 이나뜨 파르마 에스.에이. | 림프구에서의 억제 경로의 중화 |
| AU2015316993B2 (en) | 2014-09-16 | 2021-03-18 | Innate Pharma | Treatment regimens using anti-NKG2A antibodies |
| EP3209687A1 (en) | 2014-10-23 | 2017-08-30 | Innate Pharma | Treatment of cancers using anti-nkg2a agents |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| SMT202100280T1 (it) * | 2016-01-21 | 2021-07-12 | Innate Pharma | Neutralizzazione delle vie inibitorie nei linfociti |
| TWI924623B (zh) | 2018-03-13 | 2026-05-11 | 法商天賜製藥公司 | 頭頸癌之治療 |
-
2019
- 2019-05-14 WO PCT/EP2019/062305 patent/WO2019219658A1/en not_active Ceased
- 2019-05-14 US US17/054,920 patent/US12209126B2/en active Active
- 2019-05-14 CA CA3099820A patent/CA3099820A1/en active Pending
- 2019-05-14 MA MA052627A patent/MA52627A/fr unknown
- 2019-05-14 AU AU2019270277A patent/AU2019270277B9/en active Active
- 2019-05-14 IL IL278618A patent/IL278618B2/en unknown
- 2019-05-14 EA EA202092696A patent/EA202092696A1/ru unknown
- 2019-05-14 JP JP2020563542A patent/JP7531404B2/ja active Active
- 2019-05-14 EP EP19728320.3A patent/EP3793607A1/en active Pending
- 2019-05-14 TW TW108116510A patent/TW202011989A/zh unknown
- 2019-05-14 KR KR1020207035232A patent/KR102885515B1/ko active Active
- 2019-05-14 CN CN201980031725.8A patent/CN112203691A/zh active Pending
- 2019-05-14 SG SG11202011117VA patent/SG11202011117VA/en unknown
-
2024
- 2024-04-03 JP JP2024059910A patent/JP2024102055A/ja active Pending
-
2025
- 2025-01-14 AU AU2025200275A patent/AU2025200275B2/en active Active